the FDA granted 1749 OD designations and 315 OD approvals for marketing. NCEs accounted for 17.7% of OD designations and 53.7% of OD approvals. The FDA approved 635 NCEs in the study period, out of which 17.5% had OD status at the first NDA approval. Sponsors of ODs were more likely (p < 0.001) to be US companies as compared to non-US companies (64.0% vs. 54.4%) and to have one NCE approval as compared to multiple NCE during the study period (43.2% vs. 17.6%). ODs were less likely (p < 0.001) to have at least one patent listed in the OB in comparison with non-ODs (62.2% vs. 82.8%). ODs had less patents listed in the OB than non-ODs (mean 1.7 vs. 2.3) (p < 0.005). Exclusivity period was longer than the patent period for 41.4% of the ODs and 21.4% of the non-ODs that had patents listed in the OB (p < 0.001). ODs had less generic competition than non-ODs (18.0% vs. 29.6%) (p < 0.05). CON-CLUSION: US companies and companies with only one NCE approval were more likely to use the Orphan drug regulatory system. Orphan drugs have less number of patents, more exclusivity protection and less generic competition than non-orphan drugs. Kaiser Permanente Colorado, Denver, CO, USA OBJECTIVE: To compare health care utilization changes between Medicare beneficiaries with two prescription drug benefit structures who did and did not reach their respective Part D drug benefit spend threshold in 2006. METHODS: A retrospective analysis of a cohort of 28,392 Medicare Advantage beneficiaries continuously enrolled into two distinct drug benefit structures for the year prior to and after implementation of the Medicare Part D benefit. The first benefit group (Silver) had the Part D standard drug benefit threshold ($2250) while the second (Gold) had an enhanced benefit with a higher threshold ($3500). Poisson, zero-inflated Poisson, and negative binomial modeling were used to compare post-implementation utilization rates with adjustment for pre-period utilization, demographics and morbidity burden. RESULTS: A total of 1237 (6%) Silver and 526 (8%) Gold beneficiaries reached their threshold. Among both groups, beneficiaries who reached their threshold had greater morbidity burden and higher rates of pre-period inpatient admissions and medical office and ED visits (all p < 0.001). Among beneficiaries who reached their threshold, there was no change in inpatient and ED (both p > 0.05) but an increase in medical office visit (p < 0.001) utilization rates in comparable 6-month periods before and after reaching their threshold. Sub-analyses indicated that beneficiaries with the highest morbidity burden experienced higher utilization rates (all p < 0.05), but there were no differences between groups (all p > 0.05). Beneficiaries in both groups who did reach their threshold had higher post-period utilization rates (all p < 0.001) regardless of age and morbidity burden and were more likely to die (p < 0.001) compared to beneficiaries who did not reach their threshold. CONCLUSION: Although many Medicare beneficiaries navigate their drug spend threshold without experiencing increased health care utilization, those with high morbidity burdens are at risk of increased health care utilization and the potential for adverse outcomes. It is imperative that strategies be developed that help safeguard vulnerable Medicare beneficiaries. Using the national SEER-Medicare linked database, we studied patients 66 years or older diagnosed as NHL in one of the 13 SEER registry areas from 1994-2002. We grouped counties within SEER based on Medicare carrier coverage. We then estimated a regression model describing total physician reimbursement during the first cycle of chemotherapy (total Medicare part B and Medicare outpatient reimbursements within 21 days of the chemotherapy start date) to construct average Medicare chemotherapy physician reimbursement measures for these county groups. Logistic regression was performed to assess the influence of Medicare carrier chemotherapy reimbursement on the use of G-CSF. RESULTS: F test from the regression model showed statistically significant variation in the reimbursement for first cycle chemotherapy by counties grouped by carrier coverage (P value = 0.0017). We found that Medicare carrier-related chemotherapy reimbursement had a non-linear relationship with the use of G-CSF. Both linear and squared reimbursement terms were statistically significant. An increase in chemotherapy reimbursement from initially low reimbursement levels resulted in a decrease in the use of G-CSF and this relationship went away at higher chemotherapy reimbursement levels. CONCLUSION: Medicare physician reimbursement for chemotherapy varies across Medicare carriers and this variation affects the decision of physicians to prescribe G-CSF. At low chemotherapy reimbursement levels, increases in chemotherapy reimbursements decreases G-CSF prescribing. Physicians appear to compensate for lower reimbursements by increasing the intensity of their services. 
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Kaiser Permanente Colorado, Denver, CO, USA OBJECTIVE: To compare health care utilization changes between Medicare beneficiaries with two prescription drug benefit structures who did and did not reach their respective Part D drug benefit spend threshold in 2006. METHODS: A retrospective analysis of a cohort of 28,392 Medicare Advantage beneficiaries continuously enrolled into two distinct drug benefit structures for the year prior to and after implementation of the Medicare Part D benefit. The first benefit group (Silver) had the Part D standard drug benefit threshold ($2250) while the second (Gold) had an enhanced benefit with a higher threshold ($3500). Poisson, zero-inflated Poisson, and negative binomial modeling were used to compare post-implementation utilization rates with adjustment for pre-period utilization, demographics and morbidity burden. RESULTS: A total of 1237 (6%) Silver and 526 (8%) Gold beneficiaries reached their threshold. Among both groups, beneficiaries who reached their threshold had greater morbidity burden and higher rates of pre-period inpatient admissions and medical office and ED visits (all p < 0.001). Among beneficiaries who reached their threshold, there was no change in inpatient and ED (both p > 0.05) but an increase in medical office visit (p < 0.001) utilization rates in comparable 6-month periods before and after reaching their threshold. Sub-analyses indicated that beneficiaries with the highest morbidity burden experienced higher utilization rates (all p < 0.05), but there were no differences between groups (all p > 0.05). Beneficiaries in both groups who did reach their threshold had higher post-period utilization rates (all p < 0.001) regardless of age and morbidity burden and were more likely to die (p < 0.001) compared to beneficiaries who did not reach their threshold. CONCLUSION: Although many Medicare beneficiaries navigate their drug spend threshold without experiencing increased health care utilization, those with high morbidity burdens are at risk of increased health care utilization and the potential for adverse outcomes. It is imperative that strategies be developed that help safeguard vulnerable Medicare beneficiaries. NON-HODGKIN Using the national SEER-Medicare linked database, we studied patients 66 years or older diagnosed as NHL in one of the 13 SEER registry areas from 1994-2002. We grouped counties within SEER based on Medicare carrier coverage. We then estimated a regression model describing total physician reimbursement during the first cycle of chemotherapy (total Medicare part B and Medicare outpatient reimbursements within 21 days of the chemotherapy start date) to construct average Medicare chemotherapy physician reimbursement measures for these county groups. Logistic regression was performed to assess the influence of Medicare carrier chemotherapy reimbursement on the use of G-CSF. RESULTS: F test from the regression model showed statistically significant variation in the reimbursement for first cycle chemotherapy by counties grouped by carrier coverage (P value = 0.0017). We found that Medicare carrier-related chemotherapy reimbursement had a non-linear relationship with the use of G-CSF. Both linear and squared reimbursement terms were statistically significant. An increase in chemotherapy reimbursement from initially low reimbursement levels resulted in a decrease in the use of G-CSF and this relationship went away at higher chemotherapy reimbursement levels. CONCLUSION: Medicare physician reimbursement for chemotherapy varies across Medicare carriers and this variation affects the decision of physicians to prescribe G-CSF. At low chemotherapy reimbursement levels, increases in chemotherapy reimbursements decreases G-CSF prescribing. Physicians appear to compensate for lower reimbursements by increasing the intensity of their services. 
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